|
Statins,safetyandcompliance:Dealingwithsideeffects
|
|
|
J-LITJapanese Lipid Intervention Trial
|
|
|
MEGAManagement of Elevated Cholesterol in the Primary Prevention of Adult Japanese
|
|
|
Statin Tolerability and Perceived Risk for Adverse Events
|
|
|
The National Lipid AssociationStatin Safety Task Force Report
|
|
|
Questions about Liver Issues in Statin-Taking Patients
|
|
|
Transaminases and Liver Disease
|
|
|
The Incidence of Elevated Liver Biochemistries Over a 6-Month Period Among Statin Users Predominantly Atorvastatin and Simvastatin
|
|
|
Use of Simvastatin in Patients with Hepatitis C
|
|
|
Statin Tolerability and Safety– Liver Effects
|
|
|
Questions about Muscle Issues in Statin-Taking Patients
|
|
|
SomeDefinitions…
|
|
|
Reported cases of fatal rhabdomyolysis per number of prescriptions for HMG-CoA reductase inhibitors(statins) dispensed in the US from launches to May 2001
|
|
|
Rhabdomyolysis Reports as a percentage of the Total AEs on the FDA Database
|
|
|
Factors that Increase the Risk of Statin Induced Myopathy
|
|
|
Strategies to Improve Patient compliance
|
|
Share this page with your colleagues and friends: